Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajmg.a.62125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiomics in pediatric brain tumors: from images to insights.
Discov Oncol
August 2025
Department of Imaging, The Clatterbridge Cancer Centre NHS Foundation Trust, 65 Pembroke Place, Liverpool, L7 8YA, UK.
Radiomics has emerged as a promising non-invasive imaging approach in pediatric neuro-oncology, offering the ability to extract high-dimensional quantitative features from routine MRI to support diagnosis, risk stratification, molecular characterization, and outcome prediction. Pediatric brain tumors, which differ significantly from adult tumors in biology and imaging appearance, present unique diagnostic and prognostic challenges. By integrating radiomics with machine learning algorithms, studies have demonstrated strong performance in classifying tumor types such as medulloblastoma, ependymoma, and gliomas, and predicting molecular subgroups and mutations such as H3K27M and BRAF.
View Article and Find Full Text PDFOutcomes of Infants and Young Children With CNS Embryonal Tumors Using Pre-Irradiation Chemotherapy: A Decade Long Experience.
Cancer Med
August 2025
Division of Paediatric Oncology, Tata Memorial Centre, Mumbai, India.
Background: Management of infants and young children with embryonal tumors of the central nervous system remains a challenge. We report the outcomes in these children with the strategy of surgery, pre-irradiation chemotherapy, and delayed radiation.
Procedure: Children less than 3 years and diagnosed with medulloblastoma(MB), atypical teratoid rhabdoid tumor(ATRT), embryonal tumor with multilayered rosettes(ETMR), embryonal tumor tumors NOS(ET NOS) and pineoblastoma(PB), underwent standard evaluation and staging.
Cost-Effectiveness of Proton Versus Photon Therapy for Medulloblastoma Using Updated Clinical Outcomes.
Int J Part Ther
September 2025
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Purpose: The benefit of proton beam therapy (PBT) is evident in pediatric cancer, as survivors have to face long-term radiation-related side effects and lifetime costs. However, PBT's higher costs cause a challenge especially in middle-income countries. This study analyzed cost-effectiveness of PBT versus photon beam therapy (XRT) for medulloblastoma based on updated clinical outcomes within middle-income country context.
View Article and Find Full Text PDFCAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.
Front Immunol
July 2025
Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, United States.
Chimeric Antigen Receptor T (CAR-T) cell therapy offers substantial promise for the treatment of brain malignancies, yet its clinical translation remains limited. Tumors such as Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), and Medulloblastoma (MB) are associated with poor prognoses and exhibit limited responsiveness to conventional treatment modalities, including radiotherapy, chemotherapy, and surgical resection. The application of CAR-T cell therapy in these contexts faces significant challenges, primarily in terms of efficient cellular trafficking into the tumor microenvironment and access to heterogeneous tumor regions.
View Article and Find Full Text PDFRobust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing.
Acta Neuropathol Commun
June 2025
Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle Upon Tyne, UK.
Medulloblastoma comprises four principal molecular disease groups and their component subgroups, each with distinct molecular and clinical features. Group assignment is currently achieved diagnostically using Illumina DNA methylation microarray. Whole-genome sequencing (WGS) capacity is rapidly expanding in the clinical setting and the development of platform-independent, sequence-based assays of molecular group offers significant potential.
View Article and Find Full Text PDF